In addition, a synergy in controlling tumor growth between LSD1 inhibition and PD-1 blockade was observed in the B16 tumor and triple-negative breast cancer (TNBC) tumor mouse models as a result of the enhanced tumor immunogenicity, T cell infiltration, and anti-tumor T cell immunity.122,123 Furthermore, LSD1 is overexpressed in tumors compared with normal tissues in a broad of cancers, which indicates LSD1 is a promising target to enhance the effect of ICIs.122. The gene discussed is KDM1A; the disease is neoplasm.